NCT06591910View on ClinicalTrials.gov

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

September 20, 2026

Study Completion Date

September 20, 2030

Conditions
Unresectable Stage III Non-small-cell Lung Cancer
Interventions
DRUG

Chemoimmunotherapy

Induction Serplulimab combined with chemotherapy

PROCEDURE

Surgery

After induction chemoimmunotherapy, patients with tumors resectable after chemoimmunotherapy will receive surgical treatment in department of thoracic surgery.

RADIATION

Radiation

After induction chemoimmunotherapy, patients with tumors still unresectable will receive radiotherapy or other therapy.

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06591910 - Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter